Development of Zinc Chelating Resin Polymer Beads for the Removal of Cell-Free Hemoglobin
- 26 Downloads
Red blood cell (RBC) hemolysis is one of the most common storage lesions in packed RBCs (pRBC). Older units of pRBCs, especially those > 21 days old, have increasing levels of hemolysis leading to increased oxidative stress and premature platelet activation. This effect can mostly be attributed to the increase of cell-free hemoglobin (Hb). Therefore, removal of cell-free Hb from pRBCs prior to transfusion could mitigate these deleterious effects. We propose a new method for the removal of Hb from pRBCs using zinc beads. Prepared Hb solutions and pRBCs were treated with zinc beads using two different protocols. UV–Vis spectrophotometry was used to determine Hb concentrations, before and after treatment. Experiments were run in triplicate and paired t tests were used to determine significant differences between groups. Zinc beads removed on average 94% of cell-free Hb within 15 min and 78% Hb from pRBCs (p < 0.0001), demonstrating a maximum binding capacity ~ 66.2 ± 0.7 mg Hb/mL beads. No differences in RBC morphology or deformability were observed after treatment. This study demonstrates the feasibility of using zinc beads for the rapid and targeted removal of Hb from pRBC units. Further investigation is needed to scale this method for large volume removal.
KeywordsHemolysis RBC Blood products Transfusion Zinc resin Hb
Funding for this study was provided by the National Science Foundation (NSF) REU Site: Imaging and Mechanics-based Projects on Accidental Cases of Trauma Impact, Award No. 1559700 (E. Rebholz summer REU intern), and National Institutes of Health (NIH). Specifically, NIH Subcontract (NIH U01 HL077863-11, Subaward No. 0010612B, Subcontract PI: E. Rahbar) and NIH Grant R01 HL098032 (D. Kim-Shapiro). Dr. Rahbar’s startup funds were also used to support this study.
Conflict of interest
No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.
- 4.Blood Product Administration. Blood Transfusion. Washington, DC: NCLEX RN Mastery, 2019.Google Scholar
- 6.CytoSorb. Broad cytokine and toxin reduction to control deadly inflammation CytoSorbents.com. New York: CytoSorbents, 2018.Google Scholar
- 8.Donadee, C., N. J. Raat, T. Kanias, J. Tejero, J. S. Lee, E. E. Kelley, X. Zhao, C. Liu, H. Reynolds, I. Azarov, S. Frizzell, E. M. Meyer, A. D. Donnenberg, L. Qu, D. Triulzi, D. B. Kim-Shapiro, and M. T. Gladwin. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation 124:465–476, 2011.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Osei-Hwedieh, D. O., T. Kanias, C. S. Croix, M. Jessup, Z. Xiong, D. Sinchar, J. Franks, Q. Xu, E. M. Noveli, J. T. Sertorio, K. Potoka, R. J. Binder, S. Basu, A. M. Belanger, D. B. Kim-Shapiro, D. Triulzi, J. S. Lee, and M. T. Gladwin. Sickle cell trait increases red blood cell storage hemolysis and post-transfusion clearance in mice. EBioMedicine 11:239–248, 2016.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Simms, K., N. Wajih, J. Cardenas, D. B. Kim-Shapiro, and E. Rahbar. Studies of in vitro hemolysis-induced platelet activation in co-transfused packed red blood cells and platelets, 2018 (submitted).Google Scholar
- 25.Singhal, R., G. K. Annarapu, A. Pandey, S. Chawla, A. Ojha, A. Gupta, M. A. Cruz, T. Seth, and P. Guchhait. Hemoglobin interaction with GP1b alpha induces platelet activation and apoptosis: a novel mechanism associated with intravascular hemolysis. Haematologica 100:1526–1533, 2015.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.United States Environmental Protection Agency, Clement International Corporation, Syracuse Research Corporation, and United States Agency for toxic substances and disease registry. Toxicological Profile for Zinc. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, p. 17, 1994.Google Scholar
- 27.Van Reen, R. Zinc Toxicity in Man and Experimental Species. Bethesda: Naval Medical Research Center, p. 18, 2019.Google Scholar
- 28.Warner, M. A., I. J. Welsby, P. J. Norris, C. C. Silliman, S. Armour, E. D. Wittwer, P. J. Santrach, L. A. Meade, L. M. Liedl, C. M. Nieuwenkamp, B. Douthit, C. M. van Buskirk, P. J. Schulte, R. E. Carter, and D. J. Kor. Point-of-care washing of allogeneic red blood cells for the prevention of transfusion-related respiratory complications (WAR-PRC): a protocol for a multicenter randomised clinical trial in patients undergoing cardiac surgery. BMJ Open 7:e016398, 2017.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Which agarose (sepharose) to choose? 2, 4, or 6%? Crosslinked? In: A Discussion of Protein Research G Biosciences, 2014.Google Scholar
- 30.Zinc chelating resin (cat. # 786-287). edited by G-Biosciences, 2018.Google Scholar
- 31.Zinc, Serum Online. Mayo Foundation for Medical Education and Research Please provide complete details of references [30, 31] if possible.Google Scholar